|
Hepatitis B
|
0.010 |
Biomarker
|
disease |
BEFREE |
Serum YKL-40 was significantly increased in CPH patients, and was associated with Child-Pugh score and HBV infection.
|
31427175 |
2020 |
|
Portal Hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
Effect of laparoscopic splenectomy on portal vein thrombosis and serum YKL-40 in patients with cirrhotic portal hypertension.
|
31427175 |
2020 |
|
Lymphoma, T-Cell, Cutaneous
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study has suggested that YKL-40 produced from epidermal keratinocytes and CTCL cells promoted the proliferation of CTCL cells through extracellular signal-regulated kinase 1/2 pathways in autocrine and paracrine manners, leading to development of CTCL.
|
31622598 |
2020 |
|
Chronic Persistent Hepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Serum YKL-40 was significantly increased in CPH patients, and was associated with Child-Pugh score and HBV infection.
|
31427175 |
2020 |
|
Portal Vein Thrombosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the effect of LS on the formation of portal vein thrombosis (PVT) and serum levels of a fibrosis marker, YKL-40, in patients with CPH.
|
31427175 |
2020 |
|
Hypersensitive syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
YKL-40 is an important protein that plays a critical role in chronic inflammation in hypersensitivity disease.
|
31267789 |
2020 |
|
Middle Cerebral Artery Occlusion
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In microglia isolated from MCAO-injured Chi3L1 knockout mice, expression of M1 markers (iNOS, CD86, IL-1β, and IL-6) was increased and M2 markers (Arg1, Mrc1, IL-10, and IL-4Ra) was decreased.
|
31669069 |
2020 |
|
Acne Vulgaris
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study results suggest that YKL-40 might have a role in AV pathogenesis.
|
31490625 |
2019 |
|
Alcohol Use Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
During follow-up, the biomarkers of alcohol consumption, GT and CDT, in AUD patients were found to decrease in parallel with serum YKL-40 levels.
|
30769022 |
2019 |
|
Bipolar Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
The receiver operating characteristics (ROC) analysis revealed an area under the curve (AUC) of YKL-40 in the diagnosis of BD as 0.79 (95% confidence interval [CI]: 0.72-0.85) with a sensitivity of 82.7% and specificity of 68.1% at a cutoff level of 2307.1 pg/ml.
|
30617377 |
2019 |
|
Carcinoma, Transitional Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We performed immunohistochemical study to evaluate CHI3L1 expression in 2 well-defined cohorts of urothelial carcinoma, including UTUC (n = 340) and UBUC (n = 295).
|
30660494 |
2019 |
|
Celiac Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The prevalence of IgG, IgA and secretory IgA [sIgA] to chitinase 3-like protein 1 [CHI3L1] was analysed by enzyme-linked immunosorbent assays using recombinant CHI3L1 in 110 patients with Crohn's disease [CD], 95 with ulcerative colitis [UC], 126 with coeliac disease [CeD] and 86 healthy controls [HCs].
|
30753386 |
2019 |
|
Dermatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Chitinase 3-like 1 drives allergic skin inflammation via Th2 immunity and M2 macrophage activation.
|
31397016 |
2019 |
|
Epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
YKL-40 may play a possible pathogenic role in epilepsy.
|
30584894 |
2019 |
|
Gastrointestinal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
We also found that elevated serum/plasma YKL-40 had significant prognostic effects on OS in various cancer subgroups such as gastrointestinal tumors (HR, 1.37; 95% CI 1.18-1.58), ovarian cancer (HR, 2.27; 95% CI 1.69-3.06), melanoma (HR, 1.77; 95% CI 1.18-2.67), lung cancer (HR, 1.73; 95% CI 1.35-2.23), urologic neoplasms (HR, 1.61; 95% CI 1.08-2.40) and glioblastoma (HR, 1.23; 95% CI 1.07-1.42); in contrast, the prognostic effect of serum/plasma YKL-40 was not statistically significant in breast cancer (HR, 1.07; 95% CI 0.98-1.17).
|
31624472 |
2019 |
|
leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Many studies have shown that the YKL-40 gene is one of the most widely expressed genes in tumors, including leukemia, but not in healthy blood cells.
|
30426549 |
2019 |
|
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
This finding supports the idea of targeting YKL-40 as a new drug treatment of ALL and extends the use of resveratrol in antileukemia research.
|
30426549 |
2019 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
This finding supports the idea of targeting YKL-40 as a new drug treatment of ALL and extends the use of resveratrol in antileukemia research.
|
30426549 |
2019 |
|
Lichen Planus
|
0.010 |
Biomarker
|
disease |
BEFREE |
The findings in our study support the role of YKL-40 in the pathogenic process of LP and may help in treatment of lichen planus.
|
31231798 |
2019 |
|
Myositis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Serum YKL-40 was positively correlated with myositis disease activity assessment visual analogue scale, C-reactive protein, erythrocyte sedimentation rate and ferritin.
|
30019588 |
2019 |
|
Lobar Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients in the RSV group had significantly lower levels of C-reactive protein (CRP) and chitinase-3-like protein 1 (CHI3L1) than the pneumococcal pneumonia group (P < 0.05 for both).
|
31306398 |
2019 |
|
Pterygium
|
0.010 |
Biomarker
|
disease |
BEFREE |
We believe YKL-40 may play a significant role in pterygium pathogenesis.
|
29922975 |
2019 |
|
Pulmonary Eosinophilia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Study I: Serum YKL-40 levels in non-eosinophilic asthma (NEA) i.e. neutrophilic (47.77 [29.59, 74.97] ng/mL, n = 40) and paucigranulocytic (47.36 [28.81, 61.68] ng/mL, n = 31) were significantly elevated compared with eosinophilic asthma (31.05 [22.41, 51.10] ng/mL, n = 44) (P = 0.015).
|
31113430 |
2019 |
|
Respiratory Syncytial Virus Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In human subjects, YKL-40 and IL-13 levels in NPA were higher in children with RSV infection than in control subjects.
|
30402955 |
2019 |
|
Retinal Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, miR-24 and CHI3L1 might be the targets for developing more effective therapy for degenerative retinal diseases like AMD.
|
31491426 |
2019 |